Asia-Pacific Bladder Cancer Therapeutics Market by Type (Transitional Cell Bladder Cancer, Non Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder, & Rare Bladder Cancers) and By Treatment (Surgery, Chemotherapy, Immunotherapy, Radiation Therapy, & Intravesical Therapy) –Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis and Forecasts (2016 to 2021)

Asia-Pacific Bladder Cancer Therapeutics Market by Type (Transitional Cell Bladder Cancer, Non Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder, & Rare Bladder Cancers) and By Treatment (Surgery, Chemotherapy, Immunotherapy, Radiation Therapy, & Intravesical Therapy) –Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis and Forecasts (2016 to 2021)

ID: 1152 | Pages: 140 | November 2016 | Region: Asia Pacific


Asia-Pacific Bladder Cancer Therapeutics market is expected to reach USD 106.6 million by 2021 from USD 80.8 million in 2016, growing at a CAGR of 5.68% during forecast period 2016-2021. Bladder cancer is aroused due to malignancy of urinary bladder lining with epithelial cells. Bladder is an organ present at lower part of abdomen and stores urine. Over developing of these epithelial cells results in blabber cancer and it can be of many types such as transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. At present number of therapies have been evolved for the management of bladder cancers include chemotherapies, immunotherapies, surgeries, radiation therapies, and other therapies.

Rising healthcare expenditure, increasing cancer patient population, growing involvement of universities & research institutes, and rising focus of foreign pharmaceutical companies on Asian market are driving the growth of bladder cancer therapeutics market in Asia-Pacific. However, unawareness among bladder cancer patients about advanced cancer therapies and presence of more number of generic bladder cancer therapeutics are constraining the growth of bladder cancer therapeutics market in Asia-Pacific.

Asia-Pacific Bladder Cancer Therapeutics market is segmented based on type and treatment. Based on type, the market is further sub-segmented as Transitional Cell Bladder Cancer, Non Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder, and Rare Bladder Cancers. Based on treatment, the market is further segmented as Surgery, Chemotherapy, Immunotherapy, Radiation Therapy, and Intravesical Therapy.

On the basis of geographical areas, Asia-Pacific Bladder Cancer Therapeutics market is segmented as Japan, China, India, South Korea, and Australia.

The key players in Bladder Cancer Therapeutics market include, Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Celgene Corporation (U.S.).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Transitional Cell Bladder Cancer    

                                5.1.2 Non Muscle Invasive/Superficial Bladder Cancer     

                                5.1.3 Invasive Bladder Cancer    

                                5.1.4 Squamous Cell Bladder Cancer       

                                5.1.5 Adenocarcinoma of the Bladder    

                                5.1.6 Rare Bladder Cancers         

                5.2 By Treatment                            

                                5.2.1 Surgery    

                                                5.2.1.1 Transurethral Bladder Tumor Resection (TURBT)

                                                5.2.1.2 Cystectomy

                                                5.2.1.3 Urinary Diversion

                                5.2.2 Chemotherapy     

                                5.2.3 Immunotherapy   

                                5.2.4 Radiation Therapy

                                5.2.5 Intravesical Therapy           

6. Geographical Analysis                                              

                6.1 Asia-Pacific                 

                                6.1.1 Introduction           

                                6.1.2 China         

                                6.1.3 India          

                                6.1.4 Japan        

                                6.1.5 South Korea           

                                6.1.6 Australia  

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Sanofi S.A. (France)                 

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 GlaxoSmithKline plc (U.K.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 AstraZeneca plc (U.K.)                           

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 Celgene Corporation (U.S.)               

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Bladder Cancer Therapeutics Market By Region, From 2016-2021 ( USD Million )
  2. Asia-Pacific Bladder Cancer Therapeutics Market By Type, From 2016-2021 ( USD Million )
  3. Asia-Pacific Transitional Cell Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  4. Asia-Pacific Non Muscle Invasive/Superficial Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  5. Asia-Pacific Invasive Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  6. Asia-Pacific Squamous Cell Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  7. Asia-Pacific Adenocarcinoma of the Bladder Market By Region, From 2016-2021 ( USD Million )
  8. Asia-Pacific Rare Bladder Cancers Market By Region, From 2016-2021 ( USD Million )
  9. Asia-Pacific Bladder Cancer Therapeutics Market By Treatment, From 2016-2021 ( USD Million )
  10. Asia-Pacific Bladder Cancer Surgery Market By Region, From 2016-2021 ( USD Million )
  11. Asia-Pacific Bladder Cancer Chemotherapy Market By Region, From 2016-2021 ( USD Million )
  12. Asia-Pacific Bladder Cancer Immunotherapy Market By Region, From 2016-2021 ( USD Million )
  13. Asia-Pacific Bladder Cancer Radiation Therapy Market By Region, From 2016-2021 ( USD Million )
  14. Asia-Pacific Bladder Cancer Intravesical Therapy Market By Region, From 2016-2021 ( USD Million )
  15. China Bladder Cancer Therapeutics Market By Type, From 2016-2021 ( USD Million )
  16. China Bladder Cancer Therapeutics Market By Treatment, From 2016-2021 ( USD Million )
  17. India Bladder Cancer Therapeutics Market By Type, From 2016-2021 ( USD Million )
  18. India Bladder Cancer Therapeutics Market By Treatment, From 2016-2021 ( USD Million )
  19. Japan Bladder Cancer Therapeutics Market By Type, From 2016-2021 ( USD Million )
  20. Japan Bladder Cancer Therapeutics Market By Treatment, From 2016-2021 ( USD Million )
  21. South Korea Bladder Cancer Therapeutics Market By Type, From 2016-2021 ( USD Million )
  22. South Korea Bladder Cancer Therapeutics Market By Treatment, From 2016-2021 ( USD Million )
  23. Australia Bladder Cancer Therapeutics Market By Type, From 2016-2021 ( USD Million )
  24. Australia Bladder Cancer Therapeutics Market By Treatment, From 2016-2021 ( USD Million )
  25. Asia-Pacific Bladder Cancer Surgery Market By Type, From 2016-2021 ( USD Million )
  26. Asia-Pacific Transurethral Bladder Tumor Resection (TURBT) Market By Region, From 2016-2021 ( USD Million )
  27. Asia-Pacific Bladder Cancer Cystectomy Market By Region, From 2016-2021 ( USD Million )
  28. Asia-Pacific Bladder Cancer Urinary Diversion Market By Region, From 2016-2021 ( USD Million )
  29. China Bladder Cancer Surgery Market By Type, From 2016-2021 ( USD Million )
  30. India Bladder Cancer Surgery Market By Type, From 2016-2021 ( USD Million )
  31. Japan Bladder Cancer Surgery Market By Type, From 2016-2021 ( USD Million )
  32. South Korea Bladder Cancer Surgery Market By Type, From 2016-2021 ( USD Million )
  33. Australia Bladder Cancer Surgery Market By Type, From 2016-2021 ( USD Million )
Middle East and Africa Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, N...
Latin America Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Gener...
Asia-Pacific Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Genera...
Europe Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Generation s...
North America Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems (CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Gene...
Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Generation sequenci...
Middle East and Africa Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous syste...
Latin America Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, ...
Asia-Pacific Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, a...
Europe Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, anti-ca...
North America Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, ...
Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, anti-cancer dr...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, Kakatiya's Empire,
Jubilee Gardens, Hyderabad,
Telangana, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.